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Abstract
Background: Primary hepatocytes, one of the most widely used cell types for toxicological
studies, have a very limited life span and must be freshly derived from mice or even humans.
Attempts to use stable cell lines maintaining the enzymatic pattern of liver cells have been so far
unsatisfactory. Stress proteins (heat shock proteins, HSPs) have been proposed as general markers
of cellular injury and their use for environmental monitoring has been suggested. The aim of this
work is to develop a bi-transgenic hepatocyte cell line in order to evaluate the ability of various
organic and inorganic chemicals to induce the expression of the HSP70 driven reporter gene.
We previously described transgenic mice (Hsp70/hGH) secreting high levels of human Growth
Hormone (hGH) following exposure to toxic compounds in vivo and in vitro in primary cultures
derived from different organs. In addition, we also reported another transgenic model (AT/cytoMet)
allowing the reproducible immortalization of untransformed hepatocytes retaining in vitro complex
liver functions.
Results: The transgenic mouse line Hsp70/hGH was crossed with the AT/cytoMet transgenic
strain permitting the reproducible immortalization of untransformed hepatocytes. From double
transgenic animals we derived several stable hepatic cell lines (MMH-GH) which showed a highly-
differentiated phenotype as judged from the retention of epithelial cell polarity and the profile of
gene expression, including hepatocyte-enriched transcription factors and detoxifying enzymes. In
these cell lines, stresses induced by exposure to inorganic [Sodium Arsenite (NaAsO2) and
Cadmium Chloride (CdCl2)], and organic [Benzo(a)Pyrene (BaP), PentaChloroPhenol (PCP),
TetraChloroHydroQuinone (TCHQ), 1-Chloro-2,4-DiNitro-Benzene (CDNB)] compounds,
specifically induced hGH release in the culture medium.
Conclusions: MMH-GH, an innovative model to evaluate the toxic potential of chemical and
physical xenobiotics, provides a simple biological system that may reduce the need for animal
experimentation and/or continuously deriving fresh hepatocytes.
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Background
The identification of chemical and physical agents poten-
tially hazardous for human health is a great challenge
involving a great deal of time and money, since inexpen-
sive high-throughput assays are not yet available. In addi-
tion, research involving living animals conflicts with the
personal beliefs of a large strata of the population.
Transgenic technology was proposed to address the issue
of genotoxicity and toxicology [1-5]. We previously
described transgenic mice that bear the human growth
hormone (hGH) as a reporter gene whose expression is
driven by the regulatory sequences of the heat shock pro-
tein 70 gene (hsp70/hGH mice) [4]. In the blood of these
mice, high levels of hGH were specifically detected after
administration of known toxic, non-genotoxic inorganic
compounds, such as arsenic and cadmium. In addition,
we showed that hsp70/hGH  transgenic-derived primary
cells, including hepatocytes, specifically release hGH in
the culture medium after exposure to toxic inorganic
compounds.
Cultured mammalian hepatocytes retaining differentiated
hepatic functions would be greatly useful in toxicology.
However, primary hepatocytes have a very limited life
span and must be freshly derived from mice or even
humans. Various attempts to use transformed hepatocyte
cell lines or to genetically engineer primary hepatocytes
for toxicological studies have been unsatisfactory, since
they rapidly modify their repertoire of tissue-specific gene
expression including metabolising enzymes [6-9]. In this
regard, a major breakthrough came from the discovery
that the liver-specific transgenic expression of a truncated
form of the hepatocyte growth factor receptor (cytoMET)
under the control of the α1-antitrypsin (AT) promoter
reproducibly permits immortalization of untransformed
and highly-differentiated hepatocyte cell lines (MMH)
[10,11].
Based on these considerations, we crossed hps70/hGH
with AT-cytoMET mice, obtaining double transgenic mice
and from them stable hepatocyte cell lines (MMH-GH).
The results shown in the present paper indicate that these
MMH-GH cell lines, which specifically expressed the
reporter hGH gene after exposure to inorganic and organic
compounds with known toxicity, may represent a useful
tool in toxicological studies.
Results
Several stable cell lines (MMH-GH1, MMH-GH2, MMH-
GH5, MMH-GH9, MMH-GH10, MMH-GH11) were
derived from liver explants of double transgenic 18 days
post coitum embryos as described in the Methods section.
As expected, all the 6 lines tested failed to grow in soft agar
and to form tumors in nude mice (data not shown), in
accordance with previous observations showing that
cytoMET  transgenic expression renders hepatocytes per-
missive for immortalization without cellular transforma-
tion [10].
To gather further evidence on the differentiated hepatic
phenotype of these lines, we documented epithelial polar-
ity and liver specific gene expression. Immunofluores-
cence analysis showed in Figure 1 highlights the
expression and the cellular localization of polarity mark-
ers such as ZO-1 and the epithelium-specific adhesion
molecule E-cadherin in two different MMH-GH clones
and as positive and negative controls, in a well polarized
and previously described MMH line (MMHE14) and in a
undifferentiated, non polarized and transformed MMH
line (MMHE14/Myc) respectively. Both proteins are visi-
ble as a fine network on the membrane areas of cell-cell
contact, indicating that the cells of both lines retain a sim-
ple epithelial polarity. Moreover, the staining for cytok-
eratins reveals an abundant network of these intermediate
filaments, outlining the epithelial growth habit of the
cells.
In order to explore their application in toxicological stud-
ies we analyzed by RT-PCR some key enzymes involved in
the detoxifying machinery, highlighting a coherent pat-
tern of gene expression. As shown in Figure 1b, liver-
enriched transcription factors (HNFs), phase I (drug and
carcinogen-activating), phase II (detoxifying) and gluco-
neogenesis supporting enzymes are expressed in MMH-
GH lines; similar results were obtained at early (3) and
late (23) passages after the first thawing.
Six independent clones of MMH-GH cells were then tested
for their ability to respond to in vitro toxic stimulation.
Cells were treated with NaAsO2 and CdCl2 at concentra-
tions ranging from 10-5 to 10-4 M for 5 or 24 h (data not
shown). These conditions were chosen according to
results previously obtained with hsp70/hGH  transgenic
primary hepatocytes [4]. The MMH-GH5 clone, showing
a basal level of secreted hGH below the detection limit
and a high response to treatments, was selected for further
studies.
The hGH secretion and the cellular viability of MMH-GH5
and PHGH cells from hsp70/hGH mice in response to the
toxic inorganic compounds NaAsO2 and CdCl2 were eval-
uated (Fig 2). While the response to NaAsO2 was compa-
rable at each concentration tested in both cell lines, after
exposure to CdCl2 we observed differing behaviour in the
two models. PHGH showed an inverse correlation
between cadmium concentration and hGH release while
MMH-GH5 showed a linear response (panel A). This
result is based on the different viability of the two cell
populations (panel B). Notably, the MMH-GH5 cellsBMC Biotechnology 2004, 4 http://www.biomedcentral.com/1472-6750/4/5
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showed a higher cell viability after exposure to high doses
of toxic inorganic compounds, which results in a dose-
response linearity of the hGH release.
To test whether primary and immortalized hepatocytes
were able to respond also to toxic organic compounds, we
tested four known toxic agents: Benzo(a)pyrene (BaP),
considered mainly a genotoxic agent, PentaChloroPhenol
(PCP), TetraChloroHydroQuinone (TCHQ, the major in
vivo metabolite of PCP) and 1-Chloro-2,4-DiNitro-Ben-
zene (CDNB). PHGH and MMH-GH5 cells were exposed
to two different concentrations of these compounds for 1
and 5 hours. hGH levels were measured in the medium
either immediately after the treatment or after 24 hours of
recovery with control medium.
As shown in Additional file: 1, PHGH cells, while capable
of responding to TCHQ and CDNB, did not show elevated
hGH levels in response to BaP and PCP, due to the cyto-
toxicity of these compounds, as indicated by the low per-
centage of residual viable cells. On the other hand, MMH-
GH5, showing a higher viability, responded to all four
compounds, thus providing a suitable cell-based assay
also for these compounds. It is possible that this different
behaviour is due to the fact that stable cell lines better
adapt to culture conditions than primary cells and are
more resistant to toxic insults.
Discussion
In spite of many assays developed in lower organisms,
mammalian hepatocytes still represent a compulsory step
in the evaluation of toxic compounds because they carry
out modifications leading to the production of various
MMH-GHs maintain a highly-differentiated phenotype at morphological and molecular levels Figure 1
MMH-GHs maintain a highly-differentiated phenotype at morphological and molecular levels. Panel A shows 
the immunofluorescence analysis of E-Cadherin, ZO-1 and cytokeratins expression and localization in MMH-GH clones, in a 
well polarized MMHline (MMHE14) and in a transformed, undifferentiated MMH line(MMH/Myc). Phase-contrast images and 
microphotographs of E-Cadherin immunostaining represent the same fields. Panel B shows the RT-PCR analysis of RNA 
extracted from an MMH clone, from adult liver as control and from two different MMH-GH cell lines (MMH-GH5 and MMH-
GH9). The amplified fragments are shown in the left side of the panel, while in the right side the Southern Blot analysis of the 
same amplified sequences performed with oligonucleotides used as internal probes is shown. Normalization of RT-PCR was 
obtained by amplification of beta-actin cDNA. The genes considered are: liver-enriched transcription factors (HNF1a, HNF1b, 
HNF4), drug and carcinogen-activating and -detoxifying enzymes (Glutamine Synthethase, GLNS; UDP-glucuronosyl-trans-
ferase, UDP-GT; Cytochrome P450 1A1, Cyp1A1; Epoxide hydrolase, Eph) and gluconeogenesis supporting enzymes (Lactate 
dehydrogenase, LDH; Glutamate-oxaloacetate-transaminase 1, Got1; Glutamate-oxaloacetate-transaminase 2, Got2). Oligonu-
cleotides used as forward and reverse primers for PCR and as internal probes in Southern Blot analysis are listed in Additional 
file: 2, together with the NCBI accession numbers of the sequences from which they were derived.BMC Biotechnology 2004, 4 http://www.biomedcentral.com/1472-6750/4/5
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MMH-GH5 and PHGH response to toxic inorganic compounds Figure 2
MMH-GH5 and PHGH response to toxic inorganic compounds Panel A. Results represent Mean ± SE of hGH levels 
secreted by PHGH and MMH-GH5 cells after a 5 hour treatment with different concentrations of NaAsO2 (As1: 10-5 M, As2: 5 
× 10-4 M, As3: 10-4 M) and CdCl2 (Cd1: 10-5 M, Cd2: 5 × 10-4 M, Cd3: 10-4 M). Panel B. Mean ± SE of viability of PHGH and 
MMH-GH5 at the indicated treatment conditions as determined by the Trypan blue dye exclusion method. These results were 
obtained from 6 independent experiments with treatments carried out in triplicate.
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metabolites, which are the ultimate causes of toxicity
[12,13]. However, their use so far has been restricted to
two models, primary cultured hepatocytes and hepatoma
cell lines both of which have several drawbacks. Primary
hepatocytes, used as cultures or tissue slices must be con-
tinuously derived from living animals or even humans,
their functional activities decline rapidly after a few days
under conventional culture conditions and their response
is dependent on many variables, while hepatoma cell
lines lose features of the hepatocyte, such as drug- and
toxic-activating enzymes [13,14]. Engineered immortal-
ized human cell lines have also been developed, with dif-
ferent results [6-9].
To overcome these limitations, we have developed new
bi-transgenic immortalized hepatocyte cell lines, named
MMH-GH. As detailed in previous reports, the transgenic
expression of cytoMET, a truncated form of the c-MET
oncogene, permits the immortalization of hepatocytes
(MMH) that retain and perform in vitro complex liver
functions [10]. In the work reported here, we report that
these cells represent a novel tool that can be used in toxi-
cology studies. As shown above, each inorganic and
organic toxic compound tested so far caused specific hGH
release, albeit with different kinetics in agreement with
the results obtained by Ait-Aissa et al [15], who showed
that hsp70 induction is different depending on the classes
of compounds. Notably, for the correct interpretation of
these tests, both hGH levels and cellular viability parame-
ters must be taken into account.
Conclusions
We believe that MMH-GH cell lines provide a cheap,
reproducible, rapid, reliable and ethically acceptable tool
that has several innovative features. The major advantages
are: 1 – the use of stable cell lines allows a drastic reduc-
tion of animals sacrificed for toxicology research; 2 – the
cells are of the histotype most widely used for toxicologi-
cal studies; 3 – the cells retain in culture the morphology,
phenotype and functions mimicking hepatocytes in the
living animal; 4 – this assay, based on clonal cell popula-
tions, has with respect to primary cultures greater potenti-
ality for standardization; 5 – the presence of the reporter
gene under the control of a stress-responsive promoter
allows us to perform a quantitative, rapid and low-cost
assay able to detect early cell damage.
The fact that our detection system is able to identify hsp70
promoter induction at low doses ([5]; Figure 2 and Addi-
tional file: 1) is an advantage over traditional hepatocyte
culture systems which rely upon viability as the key end
point. Standardization of an in vitro assay based on MMH-
GH5 cells will allow a significant reduction in the number
of animals sacrificed, a very sensitive issue shared by both
public Institutions and pharmaceutical industries [16,17].
Several clones can be derived from a small number of
transgenic mice and can be used for a indefinite number
of tests. Moreover, cellular clones with the best features
may be selected, different species (rats or fish [18]) could
be engineered, different promoters and different reporter
genes could be used, as already suggested [5], to further
exploit the potentiality of this approach. In addition, pro-
moter elements for stress proteins of hsp genes with more
restricted responses to stress could be applicable for fur-
ther refining this system. Finally, by thoroughly investi-
gating the metabolic pathways regulated by truncated
cytoMet, human immortalized hepatocytes maintaining
features of differentiated liver cells could be produced and
used in toxicology studies.
Methods
Chemicals
NaAsO2 and CdCl2 were purchased from Merck (Darm-
stad, Germany); B(a)P, PCP, TCHQ, CDNB, were pur-
chased from SIGMA (St Louis, MO). All the cell culture
reagents were from SIGMA and all the plastic material
from Falcon (San Jose, CA).
Isolation of primary hepatocytes
The day before the treatment, the parenchymal compo-
nent of liver cells was isolated as previously described [4]
and seeded in 24 well plates in William's E medium sup-
plemented with 10% heat inactivated FCS and Pen/Strep.
After 2 hours the medium was replaced to remove floating
cells.
Derivation of hepatic stable cell lines and cell culture
The experimental protocol was approved by the Scientific
Committee of the Istituto di Tecnologie Biomediche,
CNR. The production and characterization of the two
transgenic strains (hsp70/hGH and cytoMET) used in the
present study have been previously described [4,10,11].
Homozygous mice from the two strains were crossed to
generate double heterozygous animals. Animal care and
sacrifice were performed according to the EU guidelines
[19] and hepatocytes were obtained and cultured as previ-
ously described [4,10]. Briefly, livers from 18 dpc bi-trans-
genic foetuses were dissected, mechanically dissociated
and plated at high density on collagen I (Sigma) coated
Nunc Petri dishes in RPMI 1640 containing 10% FCS, 50
ng/ml EGF, 30 ng/ml IGF II, 10 micrograms/ml insulin
(Boehringer Mannheim) and antibiotics. The cultures
were maintained without transfer for several weeks. Indi-
vidual epithelial islands were slowly expanded in collagen
I-coated dishes of increasing size, and frozen after around
25 cell generations. Passages are calculated from initial
thawing.
The day before the treatment with chemicals, MMH-GH
cells were seeded at 80% confluence in 12 well plates pre-BMC Biotechnology 2004, 4 http://www.biomedcentral.com/1472-6750/4/5
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coated with collagen in complete medium. The treatments
were performed in the same medium without FCS.
Immunofluorescence
For indirect immunofluorescence staining, cells were
grown on collagen I-coated glass cover slips, fixed by
immersion in methanol/acetone (3:7, vol/vol) for 15 min
at 20°C and then air dried. Coverslips were then incu-
bated for 1 h at room temperature in humidified atmos-
phere with the primary antibody. After three washes with
PBS, the coverslips were incubated with the secondary
fluorochrome-conjugated antibody diluted in PBS plus
3% BSA, washed repeatedly with PBS, and mounted with
70% glycerol in PBS. The samples were analyzed under
phase contrast and appropriate fluorescent light.
The antibodies were obtained and used as follows: mouse
monoclonal anti-pan-Cytocheratin antibody from Sigma
Chemical Co., diluted 1/100; rat monoclonal anti-zonula
occludens (ZO)-1 antibody from Zymed diluted 1/100;
mouse monoclonal anti-E-Cadherin antibody from Signal
Transduction Laboratories (Lexington, KY), diluted 1/
100; sheep anti-mouse Ig FITC linked whole antibody
from Amersham International, used 1/100; rabbit poly-
clonal anti-rat IgG FITC conjugated antibody from Sigma
Chemical Co., diluted 1/100.
The cell lines used as positive and negative controls of epi-
thelial polarity were MMH line E14 described in [10] and
the same cell line transduced with activated, transforming
form of cMyc E14/Myc (unpublished) respectively.
RNA analysis by RT-PCR
Single-stranded cDNAs were obtained from reverse tran-
scription of 1 microgram of total RNA extracted from
MMH, MMH-GH5 and MMH-GH9 cells and wild type
liver using oligo(dT)-primers and M-MLV reverse tran-
scriptase (Promega, Madison, WI), in a final reaction vol-
ume of 25 microliters according to the manufacturer's
conditions. The cDNAs were amplified by PCR according
to the standard protocol using forward and reverse spe-
cific primers. The PCR products were electrophoresed on
1% agarose gels and then transferred to Quiabrene Nylon
membrane (Quiagen, Germany) for hybridization. Blots
were probed with internal 32P-labeled oligonucleotides.
The amplified genes [20-23], the primers used for ampli-
fication and the internal probes are listed in Additional
file: 2, together with their NCBI accession numbers.
In vitro treatments
All the stock solutions were dissolved at the final concen-
tration in culture medium without FCS. NaAsO2, CdCl2
were dissolved in H2O at the concentration of 10-2 M as
stock solution and then diluted to 10-5 (dose 1), 5 × 10-5
M (dose 2) and 10-4 M (dose 3).
B(a)P, PCP, TCHQ and CDNB were dissolved according
to the manufacturer's instructions in different solvents at
5 mM concentration as stock solution and then diluted in
culture medium. B(a)P was administered at 10 and 50
microM, CDNB at 5 and 50 microM, while PCP and
TCHQ were administered at 50 and 100 microM concen-
trations. These concentrations were chosen on the basis of
data previously reported by Ait-Aissa et al [15].
Each treatment was carried out for 1 and 5 hours, then the
supernatant was removed, frozen at -20° and replaced
with fresh medium without FCS for another 24 hours.
Every treatment was carried out in duplicate and every
experiment was repeated at least 5 times. In every experi-
ment control treatments were included in which cells
received only culture medium.
Viability
Cell viability was determined at the end of treatments by
Trypan blue dye exclusion method, as previously
described [4].
Determination of hGH release
The concentration of hGH released in the supernatant
after the treatments was determined as previously
described [4] with an ELISA test, (hGH ELISA detection
kit, Roche). Each determination was carried out in dupli-
cate. The results were expressed as pg of hGH/106 cells.
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